Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147300
Corporate User License Price USD 6000
Corporate User License Price INR 441900
Site License Price USD 4000
Site License Price INR 294600
Request a Quote

Report Title

Premature Ejaculation-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Premature Ejaculation-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Premature Ejaculation-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Premature Ejaculation-Pipeline Review, H1 2017



Executive Summary

Premature Ejaculation-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation-Pipeline Review, H1 2017, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.

Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).

The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premature Ejaculation-Overview

Premature Ejaculation-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Premature Ejaculation-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Ejaculation-Companies Involved in Therapeutics Development

Allergan Plc

Ixchelsis Ltd

NeuroHealing Pharmaceuticals Inc

Plethora Solutions Holdings Plc

SK Chemicals Co Ltd

Premature Ejaculation-Drug Profiles

(lidocaine hydrochloride + prilocaine)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IX-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-405-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Ejaculation-Dormant Projects

Premature Ejaculation-Discontinued Products

Premature Ejaculation-Product Development Milestones

Featured News & Press Releases

Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation

Nov 11, 2014: Plethora Solutions Provides Company Update

Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU

Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment

Mar 11, 2014: Plethora Solutions Provides Company update

Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation

Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation

Jul 01, 2013: AGM Statement & PSD502 Regulatory Update

Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update

Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502

Dec 19, 2011: Plethora Provides Update On PSD502

Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation

May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting

Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA)

Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Premature Ejaculation, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Premature Ejaculation, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Premature Ejaculation-Pipeline by Allergan Plc, H1 2017

Premature Ejaculation-Pipeline by Ixchelsis Ltd, H1 2017

Premature Ejaculation-Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017

Premature Ejaculation-Pipeline by Plethora Solutions Holdings Plc, H1 2017

Premature Ejaculation-Pipeline by SK Chemicals Co Ltd, H1 2017

Premature Ejaculation-Dormant Projects, H1 2017

Premature Ejaculation-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Allergan Plc, Ixchelsis Ltd, NeuroHealing Pharmaceuticals Inc, Plethora Solutions Holdings Plc, SK Chemicals Co Ltd

Premature Ejaculation Therapeutic Products under Development, Key Players in Premature Ejaculation Therapeutics, Premature Ejaculation Pipeline Overview, Premature Ejaculation Pipeline, Premature Ejaculation Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand